Seagen Inc. Overview
Company Headquarters: Washington, US
Founded: 1997
Workforce: ~ 2,700
Company Working: Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. It offers antibody-drug conjugates (ADCs), including Padcevtm (enfortumab vedotin-ejfv), which is used to treat metastatic urothelial cancers, Adcetris (brentuximab vedotin), which is used to treat Hodgkin's lymphoma, T-cell lymphomas, and CD30-expressing lymphomas. (Tucat) Tukysa. Seagen's therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Additionally, Seagen also licenses its antibody-drug conjugate technology to several biotechnology and pharmaceutical companies. Seagen serves customers on a global scale.
Strategy
The goal of Seagen Inc. is to discover, develop, and market cutting-edge cancer therapies that will greatly enhance people's quality of life. The company is also focused on expanding its market globally through the acquisition of small companies and alliances with important actors. In addition, the aim of Seagen Inc. is to become a preeminent global oncology company that develops and markets therapies specifically for cancer. Furthermore, it is also focused on expanding its product portfolio through R&D investments.
